March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Clinical response to intravitreal Rapamycin in a retinal neovascularization model
Author Affiliations & Notes
  • Lucia Rivera Sanchez
    Ophthalmology Institute "Fundacion Hospital Nuestra Senora de la Luz" I.A.P., Mexico, Mexico
  • Alejandra Ruiz Franco
    Ophthalmology Institute "Hospital Fundacion Nuestra Senora de la Luz" I.A.P., Mexico, Mexico
  • Juan Abel Ramirez Estudillo
    Dept. Retina,
    Ophthalmology Institute "Hospital Fundacion Nuestra Senora de la Luz" I.A.P., Mexico, Mexico
  • Victor Manuel Bautista de Lucio
    Microbiology and Ocular Proteomics, Ophthalmology Institute "Fundacion Conde de Valenciana" I.A.P., Mexico, Mexico
  • Footnotes
    Commercial Relationships  Lucia Rivera Sanchez, None; Alejandra Ruiz Franco, None; Juan Abel Ramirez Estudillo, None; Victor Manuel Bautista de Lucio, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1217. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lucia Rivera Sanchez, Alejandra Ruiz Franco, Juan Abel Ramirez Estudillo, Victor Manuel Bautista de Lucio; Clinical response to intravitreal Rapamycin in a retinal neovascularization model. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1217.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To describe the clinical and fluorangiography response to intravitreal Rapamycin in a retinal neovascularization model induced with vascular endothelial growth factor (VEGF165).

Methods: : We performed a retinal neovascularization model in three New Zealand rabbits by intravitreal application of VEGF (8μg/0.1ml). Once neovascularization was developed, two rabbits where treated with 333μg/0.1ml of intravitreal Rapamycin. Rabbit without treatment was used as control. Clinical and fluorangiographyc follow was done at seventh and fourthteen day.

Results: : At third day after VEGF was applied, neovascularization of anterior segment was evidenced in all rabbits. At first week, retinal neovascularization was clinical and fluorangiography demonstrable. One rabbit developed a fibrovascular proliferation and small pre-retinal hemorrhage. Indirect ophthalmoscopy and fluorangiography showed partial regression of the neovascularization seven days after Rapamycin treatment, this regression continued until day fourthteen, where no clinical evidence of neovascularization was observed, and neither hiperfluorescence phenomenon. Likewise, there was partial regression of fibrovascular proliferation without retinal detachment.

Conclusions: : Intravitreal Rapamycin at 333μg/0.1ml concentration caused clinical and fluorangiographyc regression of retinal neovascularization in an experimental model induced by VEGF165.

Keywords: retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×